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Emerging evidence suggests that dyslipidemia is an independent risk factor for diabetic neuropathy (DN) (reviewed by Vincent
et al. 2009). To experimentally determine how dyslipidemia alters DN, we quantiﬁed neuropathic symptoms in diabetic mice
fed a high-fat diet. Streptozotocin-induced diabetic C57BL/6 mice fed a high-fat diet developed dyslipidemia and a painful
neuropathy (mechanical allodynia) instead of the insensate neuropathy (mechanical insensitivity) that normally develops in
this strain. Nondiabetic mice fed a high-fat diet also developed dyslipidemia and mechanical allodynia. Thermal sensitivity was
signiﬁcantly reduced in diabetic compared to nondiabetic mice, but was not worsened by the high-fat diet. Moreover, diabetic
mice fed a high-fat diet had signiﬁcantly slower sensory and motor nerve conduction velocities compared to nondiabetic mice.
Overall, dyslipidemia resulting from a high-fat diet may modify DN phenotypes and/or increase risk for developing DN. These
results provide new insight as to how dyslipidemia may alter the development and phenotype of diabetic neuropathy.
1.Introduction
Diabetic neuropathy (DN) is a principal chronic complica-
tion of both type 1 and type 2 diabetes and aﬀects over half
of diabetic patients [1–3]. Distal symmetric sensorimotor
polyneuropathy, the most common and widely recognized
form of DN, is a diﬀuse neuropathy characterized by both
sensory and motor nerve deﬁcits; however sensory dys-
function is the predominant feature of this neuropathy [4].
Aﬀected patients can experience a large spectrum of sensory
symptoms including chronic numbness, altered sensitivity to
pain or touch, and impaired proprioception [2, 5, 6]. There
is no deﬁnitive cure for this debilitating disease and symp-
tomatic treatments have shown limited success [7].
A dying back-type distal axon degeneration is the
common underlying feature associated with DN [8]. It is
thought that nerve dysfunction and degeneration leads to
sensorimotor deﬁcits, reduced nerve conduction velocities,
and decreased epidermal innervation, all of which are char-
acteristic signs of DN in human patients and animal models
[7, 9]. Although it is clear that hyperglycemia plays a key
role in the development and progression of DN [4, 9–12],
a combination of multiple etiologies is likely responsible for
axonal degeneration leading to the various types of neu-
ropathy in diabetic patients [4, 10, 11]. Despite extensive
study of proposed mechanisms, it remains unclear why some
patients develop insensate versus painful symptoms and how
underlying pathological mechanisms determine DN pro-
gression and phenotype.
The prevalence of societal overweight, obesity, and
physical inactivity continues to increase thus the inﬂuence of
lifestyle-related metabolic variables has become increasingly
important in terms of DN risk and progression. Data from
several large clinical trials suggest that dyslipidemia, typically
deﬁned as high serum levels of low-density lipoprotein
cholesterol (LDL-C), high triglycerides, and/or low levels
of high-density lipoprotein cholesterol (HDL-C) [13], is a
major independent risk factor for the development of DN
(reviewedin[1]).Inaddition,dyslipidemiaisassociatedwith
the onset and progression of neuropathy in both type 1 and
type 2 diabetes (reviewed in [14–16]). Body mass index has
also been independently associated with the incidence of
neuropathy in type 1 diabetic subjects [17]. Most individuals
with neuropathy associated with prediabetes have painful
small-ﬁber sensory neuropathy, are obese, and have dyslipi-
demia [12, 18–21]. Moreover, results from a cross-sectional2 Experimental Diabetes Research
study of type 2 diabetic subjects revealed that the prevalence
of DN was twofold higher in type 2 diabetic subjects with
the metabolic syndrome [22], a condition characterized by
dyslipidemia, obesity, and hyperglycemia [23]. In support of
the clinical evidence, nondiabetic mice fed a high-fat diet
exhibitdyslipidemia[24],increasedbodyweight,andpainful
neuropathy characterized by mechanical allodynia, thermal
hypoalgesia, and nerve conduction deﬁcits [24, 25].
Although diet was not assessed in the clinical studies,
it is plausible to suggest that diet may indirectly aﬀect DN
progressionandphenotypesincedyslipidemia andobesity in
adulthumanscanoftenbeattributedtoexcessenergyandfat
intake. Taken together, this evidence suggests that diet may
modulate the progression and phenotype of DN, and these
eﬀectsmay be mediated in part by diet-induced dyslipidemia
and/or excess body weight. Although neuropathy and pre-
diabetes have been documented in C57Bl/6 mice fed a high-
fat diet [24, 25], the eﬀects of a high-fat diet in conjunction
with type 1 diabetes have not been studied. Here, we report
the eﬀects of a high-fat diet on neuropathy progression and
phenotype in streptozotocin- (STZ-) induced type 1 diabetic
mice.
2. Methods
2.1. Animals and Diet. Seven-week-old male C57Bl/6 mice
were purchased from Charles River (Wilmington, Mass),
housed two mice per cage under pathogen free conditions,
and placed on a 12:12h light/dark cycle in the research sup-
port facility at the University of Kansas Medical Center. All
animalshadadlibitumaccesstofoodandwaterandwerefed
a standard diet (8604; Harlan Teklad, Madison Wisconsin;
14% kcals from fat, 32% protein, and 54% carbohydrate)
or high-fat diet (07011; Harlan Teklad; 54% kcals from fat
comprised of lard and corn oil, 21% protein, and 24%
carbohydrate). Animals in the high-fat diet group were fed
the standard diet for 1 week prior to streptozotocin (STZ)
injection and began the high-fat diet 3 hours post STZ in-
jection. All protocols and procedures were approved by the
University of Kansas Medical Center Animal Use and Care
Committee.
2.2. Diabetes Induction. A single intraperitoneal STZ injec-
tion (180mg/kg body weight; Sigma-Aldrich, St. Louis, Mo)
in 10mM sodium citrate buﬀer (pH 4.5) was administered
to 8-week-old C57Bl/6 mice to induce diabetes. Eight-week-
old nondiabetic C57Bl/6 mice were injected with 400μL
vehicle (sodium citrate) buﬀer. All mice were fasted for 3
hours before and after STZ injection. Body weight and blood
glucose (glucose diagnostic reagents, Sigma, St. Louis, MO)
were monitored 1 week after STZ injection and every week
thereafter. Mice with blood glucose levels of >300mg/dL
(>16mmol/L) were considered diabetic. STZ-injected mice
with blood glucose levels below 300mg/dL were excluded
from the study. Treatment groups are abbreviated through-
out as follows: nondiabetic standard diet (NdStd); nondia-
betic high-fat diet (NdHF); diabetic standard diet (DbStd);
diabetic high-fat diet (DbHF).
2.3. Behavioral Testing. Behavioral testing to assess charac-
teristic signs of DN including mechanical sensitivity, thermal
sensitivity, and sensorimotor ability (beam walk task) were
performed 1 week before STZ injection and subsequently
thereafter. Before each behavioral test was performed for
the ﬁrst time, mice were acclimated to the apparatus during
two separate training sessions. Immediately prior to each
behavioral test, mice were acclimated to the behavior room
for 30 minutes followed by a 30-minute acclimation on the
testing apparatus (except beam walk).
2.3.1. Mechanical Sensitivity. Mice were placed on an ele-
vated wire mesh screen (55cm above table), enclosed
individually in clear plastic cages (11 × 5 × 3.5cm), and
mechanical sensitivity was assessed using a 1.4g von Frey
monoﬁlament (Stoelting, Wood Dale, IL) which was applied
6 times to each hind paw footpad. A combined mean percent
withdrawal from a total of 12 applications was calculated per
mouse and used to calculate group means.
2.3.2. Thermal Sensitivity. Mice were placed on a Hargreaves
apparatus, and 4.0V radiant heat source was applied four
times to each hind paw footpad. Time elapsed before the
animalwithdrewthepawwasrecordedaswithdrawallatency.
A combined mean withdrawal latency (secs) was calculated
fromatotalof8applicationspermouseandusedtocalculate
group means.
2.3.3. Beam Walk. Mice were trained to traverse a 1m-long,
1.2cm diameter, wooden beam (adapted from [26, 27]). As
each animal crossed the beam, the number of times the right
or left paw slipped oﬀ the beam was counted as a footslip.
This behavioral test was recorded using a digital video
camera.Thecombinedmeannumberoffootslips/mousewas
calculated from a total of 3 trials per session and used to
calculate group means.
2.4. Nerve Conduction Velocity. At 8 weeks post-STZ and
immediately before sacriﬁce, mice were deeply anesthetized
by intraperitoneal injection with Avertin (1.25%v/v tribro-
moethanol [Sigma-Aldrich], 2.5% tert-amyl alcohol [Sigma-
Aldrich], dH2O; 250mg/kg) and motor and sensory nerve
conduction velocities were recorded according to Stevens et
al. [28] and as described previously by Muller et al. [29].
Body temperature was monitored by rectal probe and main-
tained at 37◦C.
2.5. Serum Lipids and Insulin. At 8 weeks after STZ injec-
tion and immediately following nerve conduction velocity
(NCV) studies, anesthetized mice were sacriﬁced. Blood was
collected into Eppendorf tubes, placed on ice to clot for
30 minutes, and centrifuged for 15 minutes at 3,000xg.
Serum was removed and frozen at −80◦C. Serum samples
were assayed for total cholesterol (Cholesterol Total E kit,
Wako Diagnostics) LDL-C (L-type LDL-C kit, Wako Diag-
nostics), triglycerides (triglyceride kit, Cayman Chemical),
and insulin (mouse insulin Elisa, Alpco).Experimental Diabetes Research 3
2.6. Immunohistochemistry. Anesthetized mice were sacri-
ﬁced, and tissues were dissected at 8 weeks after STZ injec-
tion.Unﬁxedlumbardorsalrootganglia(DRG)weredissect-
ed and frozen in Tissue-Tek O.C.T. Compound (OCT,
Sakura, Torrance, Calif). Hind paw footpads were dissected
and ﬁxed for 2 hours in Zamboni’s ﬁxative (4% formalde-
hyde, 14% saturated picric acid, 0.1M phosphate-buﬀered
saline [PBS, pH 7.4] at 4◦C), immersed overnight in 1% PBS
(pH 7.4 at 4◦C), and ﬁnally immersed for 4 hours in 30%
sucrose in 1X PBS (pH 7.4 at 4◦C). After freezing in OCT,
DRG and footpads were sectioned on a cryostat at 10μm
and 30μm, respectively, mounted on Superfrost Plus slides
(Fisher Scientiﬁc, Pittsburgh, Pa), and stored at 4◦C.
After thawing for 5 minutes at room temperature, slide-
mounted tissue was covered with blocking solution (0.5%
porcine gelatin, 1.5% normal donkey serum, and 0.5%
Triton-X in Superblock buﬀer; Pierce) for 1 hour at room
temperature. Slides were then incubated overnight at 4◦Ci n
primary antibody diluted in blocking solution. Slides were
washed the following day for 2 × 10min with PBST fol-
lowed by 3-hour incubation with ﬂuorochrome-conjugated
secondary antibodies diluted in PBS and blocking solution.
Following 2 × 10min washes in 1X PBS, slides were rinsed
in deionized distilled H2O, coverslipped and stored at −20◦C
(footpad sections) or cover slipped with Anti-Fade Prolong
Gold (Invitrogen, Carlsbad, Calif), and stored at room
temperature (DRG sections).
2.7. Intraepidermal Nerve Fiber Density. Rabbit anti-PGP 9.5
(1:400;Chemicon,Temecula,Calif)andAlexa-488(1:2000;
Molecular Probes, Eugene, Ore) were used to label and
visualize dermal and epidermal nerve ﬁbers. Fluorescent
digital images were acquired from epidermal regions using
a Nikon Eclipse E800 microscope. The number of nerve
ﬁbers per section that cross the epidermal-dermal border
was counted using a 40x objective in order to visualize ﬁbers
throughout the full depth of the tissue section. NIH Image
J software was used to measure each epidermal region and
intraepidermal nerve ﬁber density (IENFD) was expressed as
number of ﬁbers per millimeter of epidermis. The combined
mean IENFD from 6 images per mouse was used to calculate
group means.
2.8. Oxidative Stress. Primary antibodies (rabbit anti-nitro-
tyrosine [1:1000; Chemicon, Temecula, Calif] and rab-
bit anti-neuroﬁlament H [1:10,000, Chemicon, Temecula,
Calif]) and ﬂuorescent secondary antibodies (Alexa 488 and
Alexa 555 [both 1:2000; Molecular Probes, Eugene, Ore])
wereusedtolabelandvisualizenitratedtyrosineresiduesand
neurons, respectively, in the lumbar DRG. Six ﬂuorescent
digital images from 6 DRG sections per mouse were acquired
at 40x using a Nikon Eclipse E80i microscope. All pictures
were taken using the identical exposure time. Metamorph
software (MDS Analytical Technologies, Downingtown, Pa)
was used to circle individual neurons and quantify the
average intensity of nitrotyrosine ﬂuorescence and total area
per neuron. To ensure that each cell circled included the
area for the entire neuron, only neurons with a visible cen-
tral nucleus were included in the analysis. For each image,
background intensity was measured from a region adjacent
to the tissue. The background intensity for each image was
subtracted from the average ﬂuorescence intensity for each
neuron from that image. Group means for average nitroty-
rosine ﬂuorescence per cell were calculated for 4 diﬀerent
neuron sizes based on the following areas: 1–200μm2, 201–
400μm2, 401–600μm2,a n d≥601μm2.
2.9. Statistics. Data were analyzed using a two-factor analysis
of variance (ANOVA) or repeated measures ANOVA with
Fisher’s test of least square diﬀerence post hoc comparisons.
Statistical signiﬁcance was set at P<0.05.
3. Results
3.1. Body Weight, Glucose, and Insulin. Diabetic mice dis-
played common symptoms of diabetes, including polydipsia
and polyuria within 1 week after STZ injection. Typical with
this model, diabetic mice weighedless thantheir nondiabetic
counterparts. However, high-fat-fed diabetic mice gained
weight (+3g) compared to diabetics fed the standard diet
who lost 1.7g on average (Figure 1(a)). Nondiabetic mice
on the standard diet gradually gained 5g in body weight,
whereas high-fat-fed nondiabetic mice gained 13g over the
course of the 8-week study (Figure 1(a)). Energy intake
was not diﬀerent among nondiabetic groups (NdStd 13.5 ±
1.3kcals/day; NdHF 14.0 ± 0.5kcals/day, P>0.05 for NdStd
versusNdHF).Incontrast,diabeticmiceonthestandarddiet
consumed at least 2 times as many kcals/day compared to
all other groups (DbStd 29.7 ± 1.8kcals/day; DbHF 15.2 ±
7.8kcals/day, P<0.05 for DbStd versus NdStd, NdHF, and
DbHF).
In nondiabetic mice, high-fat feeding resulted in a mild
increase in blood glucose levels compared to nondiabetic
mice on the standard diet that maintained their blood glu-
cose levels around 120mg/dL throughout the 8-week study
(Figure 1(b)). As early as 1 week following STZ injection,
diabetic mice had signiﬁcantly higher blood glucose levels
compared to their nondiabetic counterparts (Figure 1(b)).
However, the combination of diabetes and the high-fat diet
resulted in signiﬁcantly lower blood glucose levels compared
to diabetic mice on the standard diet, but glucose levels
were still higher than both nondiabetic groups (Figure 1(b)).
Insulinlevelsweresigniﬁcantlylowerin bothdiabetic groups
compared to the nondiabetic groups on the equivalent diet
(Figure 1(c)). Finally, high-fat feeding induced hyperinsu-
linemia in nondiabetic mice (Figure 1(c)).
3.2.AHigh-FatDietInducesDyslipidemia. Nondiabeticmice
fed a high-fat diet had higher total cholesterol levels com-
pared to nondiabetic mice fed a standard diet (Figure 2(a)).
However, diabetes did not signiﬁcantly alter total cholesterol
in mice fed the standard or high-fat diet compared to their
nondiabetic counterparts (Figure 2(a)). The high-fat diet
increased LDL-C in nondiabetic mice, which mirrored the
eﬀect of high-fat feeding on total cholesterol in nondiabetic
mice (Figures 2(a) and 2(b)). Diabetes did not alter LDL-C4 Experimental Diabetes Research
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Figure1:Bodyweight(a)andbloodglucose(b)(n = 14–21micepergroup). #P<0.05and ###P<0.001:NdStdversusNdHF; ∗∗∗P<0.001:
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levels in mice fed the standard diet compared to their non-
diabetic counterparts (Figure 2(b)). Triglyceride levels were
not signiﬁcantly aﬀected by the high-fat diet in nondiabetic
mice (Figure 2(c)). Diabetic mice on a standard diet had
slightly higher triglycerides compared to their nondiabetic
counterparts, while triglycerides were signiﬁcantly higher in
the diabetic high-fat-fed group compared to the nondiabetic
high-fat-fed group (Figure 2(c)).
3.3. Sensorimotor Behavior Is Altered by High-Fat Feeding.
Previous studies of this murine strain have demonstrated
that STZ-induced diabetic C57Bl/6 mice can develop a slow-
lyprogressiveinsensateneuropathycharacterizedbyareduc-
tion in mechanical sensitivity that appears after 4 weeks of
diabetes. However, the degree to which individual cohorts
of mice develop a loss of sensation has been variable, ran-
ging from 27–50% change in sensitivity, and we have never
observed mechanical allodynia with this model, mouse
strain, and diet. [30–35]. In the current cohort of mice,
mechanical sensitivity was reduced by 11% (Figure 3(a));
however, the pattern of mechanical sensitivity remained sim-
ilar to previous studies that document STZ diabetes-induced
mechanical hypoalgesia. In striking contrast, the high-fat
dietincreasedmechanicalsensitivityinbothnondiabeticand
diabetic mice compared to their counterparts fed a stand-
arddietby35%and45%,respectively(Figure 3(a)).Diabetes
signiﬁcantly reduced thermal sensitivity in mice on the
standard diet but was not signiﬁcantly worsened by the
addition of the high-fat diet (Figure 3(b)). However, diabetic
mice fed the high-fat diet had signiﬁcantly lower thermal
sensitivity than high-fat-fed nondiabetic mice (Figure 3(b)).
A beam walk task was used to assess sensorimotor ability
at 8 weeks following STZ. The number of hind paw slipsExperimental Diabetes Research 5
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Figure 2: Serum Lipids. Blood was collected at 8 weeks following STZ from non-fasted mice. Total Cholesterol (a), LDL-Cholesterol (b),
and Triglycerides (c). Data are presented as means ± SEM (n = 3–8 mice per group). ∗∗P<0.01 and ∗∗∗P<0.001.
measured while mice traversed a wooden beam was used to
assess sensorimotor deﬁcits, and the number of slips was not
signiﬁcantly diﬀerent among any groups (Figure 3(c)).
3.4. Nerve Conduction and Epidermal Innervation. Neither
diabetes nor high-fat feeding alone altered sensory nerve
conduction velocity (Figure 4(a)). Conversely, the combina-
tion of diabetes and high-fat feeding signiﬁcantly reduced
sensory and motor nerve conduction velocities compared
to nondiabetic mice fed the high-fat diet (Figures 4(a) and
4(b)). High-fat feeding increased motor nerve conduction
velocity (MNCV) in nondiabetic mice, but MNCV was
not signiﬁcantly aﬀected by diabetes alone (Figure 4(b)).
Consistent with previous studies documenting decreased
cutaneous innervation associated with DN [30–32, 36–40],
IENFD was signiﬁcantly reduced in the hind paw footpad
skin after 8 weeks of diabetes (Figures 5(a)–5(c)). However,
the combination of the high-fat diet and diabetes did not
signiﬁcantly alter IENFD (Figure 5(c)).
3.5. Oxidative Stress. Immunohistochemistry was used to
quantify the abundance of nitrotyrosine, a marker of oxida-
tive stress, in the lumbar DRG with respect to neuron size.
Neither diabetes nor the high-fat diet signiﬁcantly altered
levels of nitrated tyrosine residues in small (Figures 6(a) and
6(b)) or large DRG neurons (Figure 6(d)). However, nitroty-
rosine ﬂuorescence was signiﬁcantly increased in medi-
um-sizedneuronsindiabeticmicefedthestandarddietcom-
pared to their nondiabetic counterparts (Figures 6(c) and
7). In addition, nitrotyrosine ﬂuorescence was signiﬁcantly
increased in diabetic mice fed the standard diet compared to
diabetic mice fed the high-fat diet (Figure 6(c)).
4. Discussion
Recent evidence indicating that dyslipidemia may increase a
diabetic patient’s risk of developing neuropathy (reviewed in
[1]), taken in conjunction with high-fat feeding studies in
rodents [24,25,41],suggestsdiet mayplayanimportant role
in modulating DN progression and phenotype. Here, our
data reveals that a high-fat diet fed to STZ-induced diabetic
C57BL/6 mice signiﬁcantly alters the phenotype of neural
symptoms by inducing a painful neuropathy (mechanical
allodynia) instead of an insensate neuropathy (mechanical6 Experimental Diabetes Research
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insensitivity) that often develops in these diabetic mice [30–
33]. In addition, our results support clinical data (reviewed
in [1]), that suggests that dyslipidemia may be an inde-
pendent risk factor for development of DN.
In numerous studies using this murine strain, STZ
dose, and standard diet, our laboratory and others have
reported that STZ-induced diabetic C57Bl/6 mice develop a
slowly progressive insensate neuropathy characterized by a
reduction in mechanical sensitivity after 4 weeks of diabe-
tes [30–33, 40]. It is important to note that our studies
with this inbred strain diﬀer from others that have reported
mechanical allodynia [42–45]. One important issue to
help explain these diﬀerences is that laboratories reporting
mechanicalhypoalgesiaobtained C57Bl/6 mice fromCharles
River or Harlan Laboratories [30–35] while laboratories
reportingmechanicalallodyniaobtainedC57Bl/6Jmicefrom
Jackson Laboratories [42–45]. In addition, mice from studies
reporting mechanical allodynia were fed an unspeciﬁed
standard mouse chow (PMI Nutrition International) during
the study while mice from studies reporting mechanical
hypoalgesia were fed a standard diet (Harlan Teklad 8604 or
Purina 5001). Although both are standard diets, antioxidant
and macronutrient composition varies signiﬁcantly between
vendors; thus it is possible that dietary diﬀerences may in
part contribute to the dichotomous neuropathy phenotype
observed in this mouse strain. It is plausible to suggest that
diabetic neuropathy may manifest diﬀerently due to varied
composition of the diet on which the animals were raised
andmaintained.Thecurrentﬁndingsareconsistentwiththis
discrepancyandpointtoanimportantroleofthedietrelated
to mechanical sensitivity and genetic background.
In the current study, we observed a slight reduction in
mechanical sensitivity, although the reduction in mechanical
sensitivity did not reach statistical signiﬁcance after 8 weeks
of diabetes in this cohort of animals. Importantly, however,
STZ-diabetic mice fed a high-fat diet displayed mechanical
allodynia, as opposed to the insensate phenotype previously
observed in this inbred mouse strain. The high-fat diet
induced a robust mechanical allodynia as mechanical sensi-
tivity was increased by 35% and 45%, respectively, in non-
diabetic and diabetic mice compared to their counterparts
fed a standard diet. This ﬁnding is particularly important
because it suggests that diet modulates DN phenotype in
rodents thus dietary manipulation could be used as a new8 Experimental Diabetes Research
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Figure 6: Nitrotyrosine expression in lumbar DRG neurons. Quantiﬁcation of average nitrotyrosine ﬂuorescence intensity per neuron in
the lumber DRG. Mean ﬂuorescence intensity was calculated for a total of approximately 10 cells per image from six images per mouse and
group means were calculated with respect to cell size. Group means for average nitrotyrosine ﬂuorescence per cell are binned by neuron size
according to area2: (a) 0–200μm2, (b) 201–400μm2, (c) 401–600μm2, and (d) ≥601μm2. Data are presented as means ± SEM (n = 3–8
mice per group). ∗P<0.05 and ∗∗P<0.01.
tool to investigate mechanisms that cause some patients to
experience insensate symptoms while others have painful
symptoms. In addition, this data is consistent with previous
studies that reported that a high-fat diet induces neuropathy
in nondiabetic mice [24, 25].
Diet-induced changes in neuropathy were not uniform
across modalities or symptoms. For example, diabetes signif-
icantly reduced epidermal innervation as previously noted
[30–32]; however, the high-fat diet alone or in combination
with diabetes did not further aﬀect IENFD. Similarly,
impaired thermal sensitivity was not exacerbated by the
high-fat diet in STZ-diabetic mice. This suggests that diabe-
tes alone may be the driving factor underlying reduced
IENFD and thermal hypoalgesia in this model.
Neitherdiabetesnorthehigh-fatdietsigniﬁcantlyaltered
gait and balance as assessed by the beam walk task. Body
weight diﬀerences due to the high-fat diet appeared to aﬀect
the beam walk task that potentially confounded this data,
increased error, and reduced our ability to detect statistically
signiﬁcant diﬀerences in hind paw footslips. In addition, gait
andbalancedeﬁcitsdetectedbyabeamwalktaskarethought
to be, in part, attributed to altered muscle spindle group
Ia innervation [29], which may not be aﬀected after only 8
weeks of diabetes.
Although sensory and motor NCV were reduced in
diabetic mice fed the high-fat diet compared to their non-
diabetic counterparts, diabetes alone did not signiﬁcantly
aﬀect NCV in the current study. Sensory and motor nerve
conduction deﬁcits are a well-documented consequence of
diabetes in rodents [28, 43, 44, 46–53] and several studies
report diabetes-induced slowed SNCV and MNCV in STZ-
diabetic C57Bl/6 mice. However, reports of diabetes-induced
nerve conduction deﬁcits can be variable, ranging from
no change in SNCV [29, 34, 35]o rM N C V[ 54, 55]u p
to approximately 30% and 20% reductions in sensory and
motor NCV, respectively [52]. Moreover, the time points
examined are important too, as onset of deﬁcits has been
reported to begin as early as 3 weeks after STZ [49]o ra sl a t e
as 3 months after STZ [56].Experimental Diabetes Research 9
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Figure 7: Representative images showing nitrotyrosine expression in the lumbar DRG from mice in each of four groups: (a) nondiabetic
standard diet, (b) nondiabetic high-fat diet, (c) diabetic standard diet, and (d) diabetic high-fat diet. Arrows indicate medium-sized neurons
expressing high levels of nitrotyrosine. Scale bar = 50μM.
It is unclear why the results from the current study
speciﬁcally diﬀer from many other previous reports of
slowedNCVinSTZ-diabeticC57Bl/6miceofsimilarageand
diabetes duration [43, 44, 49, 50], but a major contributing
factor may be the small number of animals examined, or
diﬀerencesinantioxidant andmacronutrientcomposition of
the standard diet, or even the mouse supplier (Charles River
versus Jackson Laboratories). As mentioned above, dietary
conditions may strongly impact the neuropathy phenotype.
For example, previous reports of slowed NCV in STZ-
diabetic C57Bl/6 mice of similar age and diabetes duration
obtained mice from Jackson Laboratories or other vendors
[43, 44, 49, 50] while the C57Bl/6 mice in the current study
were obtained from Charles River. In addition, the diet the
animals were fed during the previous studies [43, 44, 49]w a s
an unspeciﬁed standard mouse chow from PMI Nutrition
International while the standard diet in the current study
was from Harlan Teklad (8604) and were likely diﬀerent in
antioxidant and macronutrient composition.
Consistent with ﬁndings from the current study, other
previous studies did not detect decreases in SNCV in STZ-
diabetic C57Bl/6 mice, but in contrast to the current
results, showed diabetes-induced slowed MNCV [29, 34,
35]. However, diabetes duration was longer in the previous
studies(10,12,or16weeks)thanthecurrentstudy(8weeks).
Consistent with our current ﬁndings of NCV at 8 weeks after
STZ, Ramji et al. reported no signiﬁcant diﬀerences in SNCV
and MNCV at 2 months following STZ, and signiﬁcant
SNCV and MNCV deﬁcits were not observed until 3 months
after STZ in diabetic mice [56].
Nondiabetic mice fed the high-fat diet had signiﬁcantly
increased MNCV compared to nondiabetic mice fed the
standarddiet.Incontrast,previousstudieshavereportedsig-
niﬁcant SNCV and MNCV deﬁcits after high-fat feeding in
C57Bl/6 mice [24, 25, 41]. However, the duration of high-fat
feeding was longer (12 or 16 weeks) in the previous studies
[24, 25, 41] compared to 8 weeks of high-fat feeding in the
current study. Although MNCV was signiﬁcantly increased
in nondiabetic mice fed the high-fat diet compared to their
counterparts on the standard diet, MNCV in high-fat-fed
nondiabetic mice was 53.1±1.9 in the current study which is
similartopreviousreportsofMNCV(approximately50m/s)
in nondiabetic mice fed a standard diet [29, 43, 44, 52].
Although no known reports of high-fat feeding have shown
increased MNCV in nondiabetic mice, it is possible that
increased fat intake during a critical stage of development
(8–16 weeks) may aﬀect myelination and transiently increase
MNCV at this speciﬁc stage of development (16 weeks of
age).
Behavioral responses to sensorimotor tests incorporate
inputs from multiple axonal ﬁber types within peripheral
nerves. The von Frey method of assessing mechanical sen-
sitivity stimulates a combination of large myelinated A-beta
ﬁbersthataresensitivetolighttouchandsmallunmyelinated
C ﬁbers that are pain responsive. The Hargreaves test stim-
ulates pain and temperature-sensing C and A-delta ﬁbers,
whereas the beam walk test likely assesses contributions10 Experimental Diabetes Research
from dermal A-ﬁbers and muscle aﬀerent ﬁbers innervating
muscle spindles, both of which are important for gait,
balance, and proprioception. IENFD is an excellent tool for
quantifying small ﬁber loss, is often used when diagnosing
DN humans, and has been shown to correlate with diabetes
durationinhumanpatients[9,29,36,57].SlowedSNCVhas
been thought to reﬂect conduction deﬁcits predominately
in large ﬁbers [29], but reports documenting diabetes-
induced slowed SNCV vary as some studies report decreases
[58] while others report no change [29, 54]. The diabetic
environment aﬀects each ﬁber population diﬀerently and
the type of ﬁbers predominantly aﬀected varies with mouse
strain and in humans.
In the current study, the high-fat diet induced mechan-
ical allodynia, but diabetes-induced deﬁcits in thermal sen-
sitivity were not signiﬁcantly worsened by the addition of the
high-fat diet. Neither diabetes nor the high-fat diet signif-
icantly altered gait and balance as assessed by the beam walk
task. Apart from the robust eﬀects of the high-fat diet on
mechanical sensitivity, none of the other behavioral data
nor anatomical or physiological assessments performed here
suggest that the high-fat diet aﬀects sensorimotor behavior
or nerve morphology and function diﬀerently than diabetes
alone. It will be important to investigate how a high-fat
diet alters mechanical sensitivity, and whether this selective
eﬀect is related to speciﬁc peripheral ﬁber-type or central
processing of mechanical sensitivity in the CNS.
Here,wereportthatahigh-fatdietsigniﬁcantlyincreased
body weight in nondiabetic and diabetic mice compared
to their counterparts on a standard diet, suggesting that
the metabolic derangements that accompany diet-induced
obesity may have harmful eﬀects on nerve ﬁber function,
thereby leading to mechanical allodynia.
In addition, total cholesterol and LDL-C were signiﬁ-
cantly increased in high-fat-fed nondiabetic mice compared
to their nondiabetic counterparts on the standard diet, and
triglyceride levels were signiﬁcantly higher in STZ-diabetic
mice fed the high-fat diet compared to their nondiabetic
counterparts on the high-fat diet. Because at least one
parameter of the lipid proﬁle (serum total cholesterol, LDL-
C, or triglycerides) was increased in high-fat-fed nondiabetic
and STZ-diabetic mice, both groups could be consid-
ered dyslipidemic. Thus, diet-induced dyslipidemia may be
an underlying factor that drives mechanical allodynia in
rodents. Consistent with clinical evidence suggesting that
dyslipidemia is associated with DN onset and progression
(reviewed in [14–16]), our data supports the view that diet-
induced dyslipidemia may induce neuropathy in predia-
betic patients and modulate DN onset, progression, and/or
phenotype.
In the current study, nondiabetic mice fed the high-fat
diet exhibited pre-diabetes characterized by elevated glu-
cose levels and hyperinsulinemia. As expected, glucose was
signiﬁcantly higher in both diabetic groups compared to
their nondiabetic counterparts. However, glucose levels were
lower in high-fat-fed diabetics compared to diabetic mice on
the standard diet which is most likely explained by the lower
percentage of total kilocalories derived from carbohydrate
in the high-fat diet (24%) versus the standard diet (40%).
STZ is a selective beta islet cell toxin that kills the insulin-
producing cells in the pancreas thus, as expected, insulin
levels were signiﬁcantly lower in both diabetic groups com-
pared to their nondiabetic counterparts. Although high-fat
feeding induced mechanical allodynia in both nondiabetic
and diabetic mice, nondiabetic mice were hyperinsulinemic
whereas diabetic mice remained hypoinsulinemic after 8
weeks of high-fat feeding. Furthermore, diabetic mice on the
high-fat diet had signiﬁcantly higher glucose levels than their
nondiabetic counterparts, but mechanical sensitivity was not
diﬀerent between these groups. Thus, our data suggests that
glucose and insulin levels may not be key factors driving
high-fat diet-induced mechanical allodynia observed in the
current study.
A high-fat diet and diabetes alone have consistently
been shown to increase oxidative stress in rodents [24, 41,
59–61], and increased oxidative stress has been proposed
as a mechanism that contributes to pathogenesis of DN
(reviewed in [10, 62, 63]). Vincent and colleagues reported
that dyslipidemia leads to high levels of oxidized low-density
lipoproteins (ox-LDLs) in mice and in vitro, and oxLDLs
lead to severe DRG neuron oxidative stress and neuron
injury, thus identifying a potential mechanism by which
dyslipidemia may contribute to the development of DN [24].
In addition, the nitrosative component of free radical
and oxidant-induced injury in STZ diabetes has been
well characterized with several previous studies reporting
increased nitrotyrosine levels in DRG or spinal cord neurons
and/or sciatic nerve in STZ-diabetic mice [43–45, 50]
and rats [51, 64, 65]. In the current study, nitrotyrosine
levels in medium-sized DRG neurons (401–600μm2)w e r e
signiﬁcantly increased in diabetic mice fed the standard diet
compared to their nondiabetic counterparts. In addition,
nitrotyrosine ﬂuorescence was signiﬁcantly increased in
diabeticmicefedthestandarddietcomparedtodiabeticmice
fed the high-fat diet, suggesting that the high-fat diet did
not exacerbate elevated nitrotyrosine levels beyond eﬀects
from diabetes in this neuronal population. Nitrotyrosine
levels in small or large neurons were not signiﬁcantly altered
by diabetes. Although previous studies have not measured
nitrotyrosine with respect to neuron size, our results support
the current literature suggesting that nitrosative stress is
increased in DRG neurons of STZ-diabetic mice [42–45].
Although diabetes alone signiﬁcantly increased nitroty-
rosinelevelsinmedium-sizedDRGneurons,high-fatfeeding
alone did not signiﬁcantly alter nitrotyrosine levels in
nondiabetic or diabetic mice. In contrast, previous studies
report that nitrotyrosine is signiﬁcantly increased in sciatic
nerve after 16 weeks of high-fat feeding in C57Bl/6 mice
[25, 41]. However, it should be noted that these previous
studies assessed nitrotyrosine in the sciatic nerve after 16
weeks of high-fat feeding [25, 41] while the current study
measurednitrotyrosineinDRGneuronsafteronly8weeksof
high-fat feeding. It is plausible to suggest that during short-
term high-fat feeding (i.e., 8 weeks), compensatory mecha-
nisms to mediate high-fat diet-induced oxidative stress are
upregulated but these mechanisms become overwhelmed asExperimental Diabetes Research 11
high-fat feeding becomes longer term. These results should
be interpreted with caution because we only quantiﬁed
one oxidative stress marker in one tissue (DRG), and this
was a short-term study that lasted only 8 weeks. Although
nitrotyrosine levels were not aﬀected by the high-fat diet
alone in the DRG, it is possible that the eﬀects of diabetes
and/or the high-fat diet may have been more apparent if
we had quantiﬁed additional oxidative stress markers (i.e.,
hydroxyoctadecadienoicacid,4-hydroxynonenal,dityrosine)
in the DRG or other tissues such as plasma, isolated LDLs, or
sciatic nerve.
Little is known about the mechanisms contributing to
high-fat diet-induced mechanical allodynia, but one recent
study indicates that an extract from the Artemisia plant
(known for its anti-inﬂammatory and antinociceptive prop-
erties) alleviates high-fat diet-induced mechanical allodynia
and reduces 12/15 lipoxygenase (regulates proinﬂammatory
cytokine production) upregulation, suggesting that inﬂam-
mation may play a role in high-fat diet-induced neuropathy
[41]. Proinﬂammatory cytokines and chemokines have been
widely implicated in chronic pain and are thought to con-
tribute to the central sensitization that results in mechanical
allodynia [66–69]. Importantly, obesity is associated with
chronic low-grade inﬂammation [70, 71], and a high-fat
diet increases the proinﬂammatory cytokines IL1-β,t u m o r
necrosis factor alpha (TNF-α), C-reactive protein (CRP),
and IL1-6 and stimulates inﬂammatory signaling in adipose,
serum, liver, and brain [72–76]. Along with glia and ma-
crophages [77–82], adipose is an important source of proin-
ﬂammatory cytokines that may upregulate cytokine pro-
duction due to increased adipose resulting from a high-fat
diet [72, 73]. Therefore, a proinﬂammatory environment in
the spinal cord may be a key mechanism in the development
of mechanical allodynia associated with diabetes and/or a
high-fat diet. Future studies will investigate the role of spinal
inﬂammationinhigh-fatdiet-inducedmechanicalallodynia.
5. Conclusions
These results demonstrate that a high-fat diet fed to
STZ-induced diabetic C57BL/6 mice signiﬁcantly alters the
phenotype of neural symptoms by inducing a painful
neuropathy (mechanical allodynia) instead of the insensate
neuropathy (mechanical insensitivity) that we have pre-
viously observed in this inbred strain. In addition, our
results support previous studies [24, 25] that show that
a high-fat diet fed to nondiabetic mice can induce pre-
diabetes and neuropathy. In conclusion, dyslipidemia result-
ing from a high-fat diet may modify DN phenotype and/or
increase risk for developing DN. Furthermore, the metabolic
derangements that accompany diet-induced obesity may
have harmful eﬀects on nerve ﬁber function thereby leading
to mechanical allodynia. These results may provide some
insight into why some patients develop painful versus
insensate neuropathy.
Although the ability of a high-fat diet to induce mechan-
ical allodynia is novel, little is known about the mechanisms
responsible for this robust painful DN phenotype in this
model thus further study is warranted. Positive outcomes
from future studies could lead to dietary modiﬁcations
and/or increased use of treatments that improve dyslipi-
demia (i.e., omega 3 fatty acid supplementation, statins,
or exercise) as therapeutic interventions for patients with
painful diabetic neuropathy.
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